Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results

Authors: Panés, Julián, Colombel, Jean-Frederic, D’Haens, Geert R., Schreiber, Stefan, Panaccione, Remo, Peyrin-Biroulet, Laurent, Loftus, Edward V., Jr., Danese, Silvio, Tanida, Satoshi, Okuyama, Yusuke, Louis, Edouard, Armuzzi, Alessandro, Ferrante, Marc, Vogelsang, Harald, Hibi, Toshifumi, Watanabe, Mamoru, Lefebvre, Jessica, Finney-Hayward, Tricia, Sanchez Gonzalez, Yuri, Doan, Thao T., Mostafa, Nael M., Ikeda, Kimitoshi, Xie, Wangang, Huang, Bidan, Petersson, Joel, Kalabic, Jasmina, Robinson, Anne M., Sandborn, William J.

Source: In Gastroenterology June 2022 162(7):1891-1910

Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results

Authors: D’Haens, Geert R., Sandborn, William J., Loftus, Edward V., Jr., Hanauer, Stephen B., Schreiber, Stefan, Peyrin-Biroulet, Laurent, Panaccione, Remo, Panés, Julián, Baert, Filip, Colombel, Jean-Frederic, Ferrante, Marc, Louis, Edouard, Armuzzi, Alessandro, Zhou, Qian, Goteti, Venkata S., Mostafa, Nael M., Doan, Thao T., Petersson, Joel, Finney-Hayward, Tricia, Song, Alexandra P., Robinson, Anne M., Danese, Silvio

Source: In Gastroenterology June 2022 162(7):1876-1890

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Authors: Feagan, Brian G, Panés, Julián, Ferrante, Marc, Kaser, Arthur, D'Haens, Geert R, Sandborn, William J, Louis, Edouard, Neurath, Markus F, Franchimont, Denis, Dewit, Olivier, Seidler, Ursula, Kim, Kyung-Jo, Selinger, Christian, Padula, Steven J, Herichova, Ivona, Robinson, Anne M, Wallace, Kori, Zhao, Jun, Minocha, Mukul, Othman, Ahmed A, Soaita, Adina, Visvanathan, Sudha, Hall, David B, Böcher, Wulf O

Source: In The Lancet Gastroenterology & Hepatology October 2018 3(10):671-680

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Authors: Colombel, Jean-Frederic ^*, Panaccione, Remo, Bossuyt, Peter, Lukas, Milan, Baert, Filip, Vaňásek, Tomas, Danalioglu, Ahmet, Novacek, Gottfried, Armuzzi, Alessandro, Hébuterne, Xavier, Travis, Simon, Danese, Silvio, Reinisch, Walter, Sandborn, William J, Rutgeerts, Paul, Hommes, Daniel, Schreiber, Stefan, Neimark, Ezequiel, Huang, Bidan, Zhou, Qian, Mendez, Paloma, Petersson, Joel, Wallace, Kori, Robinson, Anne M, Thakkar, Roopal B, D'Haens, Geert

Source: In The Lancet 23 December 2017-5 January 2018 390(10114):2779-2789

Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease

Authors: Tanida, Satoshi, Inoue, Nagamu, Kobayashi, Kiyonori, Naganuma, Makoto, Hirai, Fumihito, Iizuka, Bunei, Watanabe, Kenji, Mitsuyama, Keiichi, Inoue, Takuya, Ishigatsubo, Yoshiaki, Suzuki, Yasuo, Nagahori, Masakazu, Motoya, Satoshi, Nakamura, Shiro, Arora, Vipin, Robinson, Anne M., Thakkar, Roopal B., Hibi, Toshifumi

Source: In Clinical Gastroenterology and Hepatology May 2015 13(5):940-948

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

Authors: Osterman, Mark T., Sandborn, William J., Colombel, Jean-Frederic, Robinson, Anne M., Lau, Winnie, Huang, Bidan, Pollack, Paul F., Thakkar, Roopal B., Lewis, James D.

Source: In Gastroenterology April 2014 146(4):941-949

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

Authors: Colombel, Jean–Frédéric, Rutgeerts, Paul J., Sandborn, William J., Yang, Mei, Camez, Anne, Pollack, Paul F., Thakkar, Roopal B., Robinson, Anne M., Chen, Naijun, Mulani, Parvez M., Chao, Jingdong

Source: In Clinical Gastroenterology and Hepatology March 2014 12(3):414-422

Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials

Authors: Sandborn, William J., Colombel, Jean-Frederic, Panés, Julian, Castillo, Majin, Robinson, Anne M., Zhou, Qian, Yang, Mei, Thakkar, Roopal

Source: In Journal of Crohn's and Colitis 15 December 2013 7(12):958-967

The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide

Authors: Robinson, Anne M, Bannister, Mark, Creeth, Jonathan E, Jones, Malcolm N ^*

Source: In Colloids and Surfaces A: Physicochemical and Engineering Aspects 2001 186(1):43-53

Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.

Authors: Chen, Baili, Gao, Xiang, Zhong, Jie, Ren, Jianlin, Zhu, Xuan, Liu, Zhanju, Wu, Kaichun, Kalabic, Jasmina, Yu, Zhuqing, Huang, Bidan, Kwatra, Nisha, Doan, Thao, Robinson, Anne M., Chen, Min-Hu

Source: Therapeutic Advances in Cardiovascular Disease; 7/16/2020, p1-13, 13p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

The use of immunoliposomes for specific delivery of antimicrobial agents to oral bacteria immobilized on polystyrene.

Authors: Robinson, Anne M.¹, Creeth, Jonathan E.², Jones, Malcolm N.¹

Source: Journal of Biomaterials Science -- Polymer Edition. 12/20/2000, Vol. 11 Issue 12, p1381-1393. 13p. 6 Graphs.

Subject Terms: *ANTIBACTERIAL agents, *LIPOSOMES, *CHLORHEXIDINE, *BACTERICIDES

945 HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY

Authors: Colombel, Jean Frederic, Panes, Julian, D'Haens, Geert R., Schreiber, Stefan, Panaccione, Remo, Peyrin-Biroulet, Laurent, Loftus, Edward V., Danese, Silvio, Louis, Edouard, Armuzzi, Alessandro, Ferrante, Marc, Vogelsang, Harald, Lefebvre, Jessica, Doan, Thao, Xie, Wangang, Huang, Bidan, Petersson, Joel H., Kalabic, Jasmina, Robinson, Anne M., Sandborn, William J.

Source: In Gastroenterology May 2020 158(6) Supplement 1:S

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

Authors: Loftus, Edward V, Reinisch, Walter, Panaccione, Remo, Berg, Sofie, Alperovich, Gabriela, Bereswill, Mareike, Kalabic, Jasmina, Petersson, Joel, Thakkar, Roopal, Robinson, Anne M, D'Haens, Geert

Source: Inflammatory Bowel Diseases; Sep2019, Vol. 25 Issue 9, p1522-1531, 10p

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Authors: Panaccione, Remo, Löfberg, Robert, Rutgeerts, Paul, Sandborn, William J, Schreiber, Stefan, Berg, Sofie, Maa, Jen-Fue, Petersson, Joel, Robinson, Anne M, Colombel, Jean-Frederic

Source: Journal of Crohn's & Colitis; Jun2019, Vol. 13 Issue 6, p725-734, 10p